Ironwood Pharmaceuticals Whittled Down Barrons Article Out Today
Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS analyst Andrew Peters maintained a Buy rating and price target of $140 on Esperion Therapeutics (NASDAQ: ESPR)
nice : )
( JUNO )
4/20/15 CAR-Ts Drugs Melt Tumors In New Study, Leading A Cancer Revolution
like this one
- Aduro Biotech Inc's initial public offering has been priced, valuing the cancer immunotherapy drug developer at about $1 billion. Shares of Aduro are expected to start trading on Wednesday on the Nasdaq under the symbol "ADRO."
3 Top-Ranked Stocks to Beat Earnings This Quarter( GPRO )4/10/15